238 related articles for article (PubMed ID: 36406148)
21. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
Front Oncol; 2022; 12():988680. PubMed ID: 36203428
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
[TBL] [Abstract][Full Text] [Related]
23. Identification of cuproptosis-related lncRNA for predicting prognosis and immunotherapeutic response in cervical cancer.
Kong X; Xiong Y; Xue M; He J; Lu Q; Chen M; Li L
Sci Rep; 2023 Jul; 13(1):10697. PubMed ID: 37400520
[TBL] [Abstract][Full Text] [Related]
24. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.
Jiang J; Chu D; Lai X; Liu L; Tao J
Comput Math Methods Med; 2022; 2022():6314182. PubMed ID: 36388161
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
26. A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma.
Zhang G; Sun J; Zhang X
Sci Rep; 2022 Jul; 12(1):11325. PubMed ID: 35790864
[TBL] [Abstract][Full Text] [Related]
27. [Cuproptosis-related lncRNAs to predict biochemical recurrence of prostate cancer].
Zhao XD; Li Y; Wang ZH; Liu Z; Chen YH; Gu YF; Shang XJ; Xu S
Zhonghua Nan Ke Xue; 2023 Feb; 29(2):120-130. PubMed ID: 37847083
[TBL] [Abstract][Full Text] [Related]
28. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
29. Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma.
Sun Q; Qin X; Zhao J; Gao T; Xu Y; Chen G; Bai G; Guo Z; Liu J
Apoptosis; 2023 Feb; 28(1-2):247-262. PubMed ID: 36344660
[TBL] [Abstract][Full Text] [Related]
30. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
31. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
32. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer.
Xu QT; Wang ZW; Cai MY; Wei JF; Ding Q
Front Pharmacol; 2022; 13():1115608. PubMed ID: 36699089
[No Abstract] [Full Text] [Related]
33. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
34. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
Tu H; Zhang Q; Xue L; Bao J
Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
36. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
37. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
38. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
39. A prognostic cuproptosis-related lncRNA predictive signature for bladder cancer patients.
Jiang S; Zhang J; Fan Q; Li Z; Dou R; Lin Z; Chen Z; Xu Y; Huang Z; Lan J; Lin W; Xu S; Gao X; Li M
Hum Cell; 2023 Mar; 36(2):798-811. PubMed ID: 36709471
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer.
Wei C; Liang Q; Li X; Li H; Liu Y; Huang X; Chen X; Guo Y; Li J
J Cell Biochem; 2019 Sep; 120(9):14916-14927. PubMed ID: 31016791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]